Eliem Therapeutics Inc Aktie News

Biotech-Aktien fielen am Mittwoch weitgehend, wobei Rapport Therapeutics, Climb Bio und Cullinan Therapeutics zu den am härtesten getroffenen Titeln gehörten.

Climb Bio drehte am Donnerstag den Kurs trotz potenziell "best-in-class" Daten für seine experimentelle Behandlung von Nierenerkrankungen um.

~29-tägige Halbwertszeit. Eine einzelne 320-mg-Dosis von CLYM116 führte zu nahezu vollständiger APRIL-Unterdrückung und 60–75 % Unterdrückung von IgA/Gd-IgA1 über 12 Wochen. CLYM116 wurde generell gut vertragen, ohne schwerwiegende unerwünschte Ereignisse, dosisbegrenzende Toxizitäten oder Hypogammaglobulinämie. Die Phase-2-NAVIGATE-2-Studie bei IgA-Nephropathie läuft; erste Daten werden in H1 ...

Data demonstrate favorable safety and tolerability profile, robust B-cell depletion, and encouraging platelet responses in heavily pretreated patients with primary immune thrombocytopenia Enrollment ongoing in the high dose cohort, with additional data anticipated by year-end 2026 WELLESLEY HILLS, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechn...

Company to share additional CLYM116 clinical data and plans for further development at R&D Spotlight in late summer

WELLESLEY HILLS, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced upcoming presentations for its CLYM116 and budoprutug programs at the European Renal Association Congress 2026, which will be held in Glasgow, Scotland June 3-6, 2026.

WELLESLEY HILLS, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced an upcoming presentation on its budoprutug program at the European Hematology Association (EHA) 2026 Congress, which will be held in Stockholm, Sweden June 11-14, 2026.

WELLESLEY HILLS, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that members of its executive team will participate in the upcoming conferences detailed below.